AI PRICE FORECAST
IQV Stock Forecast & AI Price Prediction
IQVIA Holdings · Healthcare · Diagnostics & Research
IQV live signal snapshot
IQV last traded at $274.53, down 0.23% on the session, trading 3.5% below its 52-week high of $284.50 and 77.7% above its 52-week low of $154.50. The model's verdict for IQV right now: BUY (71% confidence). Short-term moving averages are mixed right now, without a clean bullish or bearish stack forming yet. The model's one-month path points toward roughly $284.14 (3.5% from here).
On the 14-day relative strength index, IQV reads 46.0, close to the midpoint, so momentum gives neither side an edge. Its MACD line is above its signal line with a positive histogram (0.31) — upward momentum is accelerating. The 50-day moving average ($267.40) sits 26.9% above the 200-day ($210.72) — a "golden cross" structure that typically supports the longer-term uptrend.
The average 12-month target from 18 Wall Street analysts is $311.89 (range $268.00–$346.00) — 13.6% upside from where IQV trades now. The current recommendation trend leans bullish: 18 Buy/Strong Buy ratings vs 0 Sell/Strong Sell (and 2 Hold).
Live figures from real market data feeds, current as of the last site build. Open the interactive IQV dashboard for numbers updated throughout today's session.
About IQVIA Holdings
IQVIA Holdings Inc. (IQV) is a diagnostics & research company in the healthcare sector, headquartered in Durham, NC, United States. IQVIA Holdings Inc. provides clinical research services, commercial insights, and healthcare intelligence to the life sciences and healthcare industries in the Americas, Europe, Africa, and the Asia-Pacific. It has a market value of about $45.2 billion and roughly 95,000 full-time employees. Its beta of 1.17 means it has historically moved roughly in line with the market.
IQV performance vs. the market
Year to date, IQV has gained 21.8%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 28.9%, 17.4 points better than the S&P 500. The last month (+5.3%) continues the three-month advance (+13.7%).
| Period | IQV | Sector (XLV) | S&P 500 |
|---|---|---|---|
| 1 month | +5.3% | +11.4% | −2.3% |
| 3 months | +13.7% | +12.2% | −2.3% |
| Year to date | +21.8% | +22.1% | +11.4% |
| 1 year | +28.9% | +28.3% | +11.5% |
IQVIA Holdings financials at a glance
In the quarter ended Sep 30, 2026, IQVIA Holdings reported revenue of $4.4 billion and net income of $350 million (a 7.9% net margin). Revenue was up 8.0% from the same quarter a year earlier. The stock trades at a price-to-earnings ratio of 33.4 on trailing earnings of $8.22 per share. Trailing free cash flow was $2.1 billion, and total debt equals 240% of shareholders' equity.
| Quarter ended | Revenue | Net income |
|---|---|---|
| Sep 30, 2026 | $4.4B | $350M |
| Jun 30, 2026 | $4.4B | $256M |
| Mar 31, 2026 | $4.2B | $274M |
| Dec 31, 2025 | $4.4B | $514M |
IQV vs. its peers
Against 5 of its largest healthcare peers, IQV's +21.8% year-to-date return beats 2 of them. The strongest of the group this year is Eli Lilly and (LLY, +33.7%).
| Company | Price | YTD | P/E | AI verdict |
|---|---|---|---|---|
| IQVIA Holdings (IQV) | $274.53 | +21.8% | 33.4 | BUY |
| Thermo Fisher Scientific (TMO) | $717.71 | +23.9% | 37.9 | BUY |
| Danaher (DHR) | $235.31 | +2.8% | 39.0 | BUY |
| IDEXX Laboratories (IDXX) | $702.59 | +3.9% | 47.3 | BUY |
| Agilent Technologies (A) | $176.95 | +30.0% | 34.9 | BUY |
| Eli Lilly and (LLY) | $1,437.29 | +33.7% | 46.7 | BUY |
IQV stock: common questions
What is the IQV stock price target?
18 Wall Street analysts put the average 12-month target at $311.89, in a range of $268.00–$346.00, versus a recent price of $274.53. Stock Pulse 247's model projects about $284.14 over the next month.
Is IQV a buy right now?
Our AI model currently rates IQV a BUY at 71% confidence. Among analysts, 18 rate it Buy or Strong Buy, 2 Hold and 0 Sell. Neither is personal advice — weigh them with your own research and risk tolerance.
How has IQV stock performed this year?
Year to date, IQV has gained 21.8%, ahead of the S&P 500 (+11.4%) and behind the healthcare sector fund XLV (+22.1%). On a one-year view it is up 28.9%, 17.4 points better than the S&P 500. The last month (+5.3%) continues the three-month advance (+13.7%).
What is IQV's 52-week high and low?
IQV has traded between $154.50 and $284.50 over the past 52 weeks; at $274.53 it is 3.5% below its 52-week high of $284.50 and 77.7% above its 52-week low of $154.50.
What sector is IQV in, and who are its peers?
IQV is in the healthcare sector (diagnostics & research). Its largest peers on Stock Pulse 247 include Thermo Fisher Scientific (TMO), Danaher (DHR), IDEXX Laboratories (IDXX), Agilent Technologies (A).
How accurate is the IQV forecast?
It's a model estimate from price history, technical indicators and analyst targets, not a guarantee — no model predicts short-term moves reliably. Use it as one input alongside your own research.
How this works: the forecast combines IQV's price history, momentum indicators (RSI, MACD, moving averages), volatility and analyst targets into one estimate. It's a model, not a guarantee.